<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7785359</article-id><article-id pub-id-type="doi">10.1155/2020/1062325</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Pharmacological Network Reveals the Active Mechanism of Qi-Replenishing, Spleen-Strengthening, Phlegm-Dispelling, and Blood-Nourishing Fufang on Coronary Heart Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Fan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yue</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zheng</surname><given-names>Sicheng</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dang</surname><given-names>Boyi</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jianan</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9864-8478</contrib-id><name><surname>Zhang</surname><given-names>Zhe</given-names></name><email>zhangfanliuyue@163.com</email><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="I1">
<sup>1</sup>Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, China</aff><aff id="I2">
<sup>2</sup>Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, China</aff><author-notes><fn fn-type="other"><p>Academic Editor: Vincenzo De Feo</p></fn></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>29</day><month>12</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>12</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>2020</volume><elocation-id>1062325</elocation-id><history><date date-type="received"><day>1</day><month>7</month><year>2020</year></date><date date-type="rev-recd"><day>30</day><month>10</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>11</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Fan Zhang et al.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>This study aimed to investigate the potential targets and pathways of qi-replenishing, spleen-strengthening, phlegm-dispelling, and blood-nourishing Fufang in the treatment of coronary heart disease (CHD). The composition of Fufang was identified, followed by screening of the active components using ADME. The targets of active components were predicted and screened based on the TCMSP and BATMAN databases and were cross-validated using the CTD database and DisGeNET. A functional enrichment analysis was performed using the ClueGO&#x02009;+&#x02009;CluePedia plugins and clusterProfiler in the R package. The protein-protein interaction (PPI) network was constructed using the STRING database and Cytoscape. Finally, a pharmacological network was constructed. A total of 27 overlapping targets were obtained after cross-validation. ALB, IL-6, and TNF were the hub genes in the PPI network. The pharmacological network included 59 nodes and 189 relation pairs. Among the 59 nodes, there were 2 herbal medicine nodes (<italic>Salvia miltiorrhiza</italic> and <italic>Astragalus mongholicus</italic>), 8 chemical component nodes (magnesium lithospermate B, neocryptotanshinone II, heteratisine, daphneolone, tanshinone IIA, tanshinone IIB, soyasapogenol B, and astragaloside II), 27 target protein nodes (such as ALB, TNF, IL-6, NFKB1, APOA1, APOA2, CYP1A1, and CYP1A2), and 22 pathway nodes (such as the toll-like receptor signaling pathway, IL-17 signaling pathway, and TNF signaling pathway). Therefore, we found that the genes TNF, IL-6, NFKB1, ALB, CYP1A1, CYP1A2, APOA1, and APOA2 might be important targets of the key active compounds neocryptotanshinone II and astragaloside II. These genes targeted by the key active compounds might regulate inflammation-related pathways and the level of albumin and cholesterol in CHD.</p></abstract><funding-group><award-group><funding-source>National Program on Key Basic Research Project (973 Program)</funding-source><award-id>2013CB531704</award-id></award-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>81703970</award-id></award-group><award-group><funding-source>Open Foundation project of key Laboratory of Theory and Application of Viscera in Chinese Medicine</funding-source><award-id>zyzx1607</award-id><award-id>zyzx1808</award-id></award-group><award-group><funding-source>Department of Education of Liaoning Province</funding-source><award-id>L201715</award-id></award-group></funding-group></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Cardiovascular diseases are the leading cause of deaths in the world, accounting for more than twice the number of deaths caused by cancers, and have been a huge economic burden on the healthcare and society [<xref rid="B1" ref-type="bibr">1</xref>]. Coronary heart disease (CHD) is the most common cardiovascular disease, characterized by the formation of atherosclerotic plaques [<xref rid="B2" ref-type="bibr">2</xref>]. Risk factors for CHD include various aspects, aside from age and gender, such as dyslipidemia, hypertension, nutritional disorders, obesity, diabetes, and smoking [<xref rid="B3" ref-type="bibr">3</xref>]. The major cause of CHD is coronary atherosclerosis, which narrows or progressively occludes the lumen of the blood vessels, resulting in acute and temporary ischemia and hypoxia of the myocardium [<xref rid="B4" ref-type="bibr">4</xref>]. It was named &#x0201c;thoracic obstruction&#x0201d; according to the traditional Chinese medicine (TCM) theory [<xref rid="B5" ref-type="bibr">5</xref>].</p><p>TCM has been used in the treatment of CHD for thousands of years and has achieved certain curative effects [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>]. Studies have reported the roles of TCM. For example, based on a blinded randomized controlled trial, Chen et al. showed that Huoxue Huayu therapy is an effective and safe therapy for patients with CHD after percutaneous coronary intervention; it works by decreasing the degree of restenosis and improving the revascularization rate [<xref rid="B8" ref-type="bibr">8</xref>]. Liu et al. suggested that Radix <italic>Salvia miltiorrhiza</italic> compounds could decrease the risk of CHD by improving the biochemical indices (reducing the levels of triglycerides, cholesterol, and lipids, while increasing the levels of apolipoprotein A/B/E and total bilirubin) of patients with CHD [<xref rid="B9" ref-type="bibr">9</xref>]. In addition, Gong et al. found that Radix <italic>Salvia miltiorrhiza</italic>, Rhizoma Chuanxiong, Radix Astragali, and other herbs were frequently used for the treatment of CHD as evidenced by a literature review covering the recent 20 years [<xref rid="B5" ref-type="bibr">5</xref>]. Although many TCMs have been reported to show curative effects when used for CHD, their widespread applications are also hampered due to a lack of rigorous clinical trials and their complex compositions, as well as their unclear pharmacological mechanisms.</p><p>Based on the TCM theory, the spleen is connected to the heart meridians, and their functions are compatible, so the malfunctioning of the spleen can lead to changes in the heart function. Guanlin Yang proposed the method of &#x0201c;Treatment According with the Spleen&#x0201d; and developed a qi-replenishing, spleen-strengthening, phlegm-dispelling, and blood-nourishing (QSBD) TCM granule for the treatment of CHD [<xref rid="B10" ref-type="bibr">10</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>]. They found that the QSBD TCM granule showed obvious effects on stable angina pectoris associated with CHD. However, its pharmacological mechanisms are still unclear. Network pharmacology refers to the integrated analysis of a system biology network and pharmacology, which is in accordance with the core concept of the holistic philosophy of TCM, and provides insight into the detailed compound-target and target-pathway relationships of herbs used to treat complicated diseases [<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>]. Therefore, the pharmacological network of the QSBD TCM granule on CHD was investigated in this study to further uncover its potential targets and pathways.</p></sec><sec id="sec2"><title>2. Materials and Methods</title><sec id="sec2.1"><title>2.1. Candidate Components in QSBD TCM Granules</title><p>Information from all components of the four main Chinese medicinal herbs in the QSBD TCM granule (including <italic>Astragalus mongholicus</italic>, bighead atractylodes rhizome, Rhizoma Pinelliae, and <italic>Salvia miltiorrhiza</italic>) was retrieved from the TCMSP database [<xref rid="B16" ref-type="bibr">16</xref>] (http://lsp.nwu.edu.cn/browse.php?qc=herbs), including molecule name, molecular weight, AlogP, Hdon/Hacc, oral bioavailability (OB), Caco-2, blood-brain barrier, drug likeness (DL), and drug half-life. Supplemental <xref ref-type="supplementary-material" rid="supplementary-material-1">Figure 1</xref> shows the workflow of this study.</p></sec><sec id="sec2.2"><title>2.2. Screening Effective Composition of Herbs</title><p>All the components were screened using the absorption, distribution, metabolism, and excretion (ADME) model [<xref rid="B17" ref-type="bibr">17</xref>] from the TCMSP database. OB is one of the most important pharmacokinetic parameters, and components with more than 30% OB are considered to have high bioavailability, a crucial index in evaluating the DL of a potentially effective component. Compounds with a threshold of OB&#x02009;&#x02265;&#x02009;30 and DL&#x02009;&#x02265;&#x02009;0.18 were screened as effective components.</p></sec><sec id="sec2.3"><title>2.3. Prediction of Drug Targets</title><p>The protein targets of the effective components were predicted using the TCMSP database and the BATMAN-TCM database [<xref rid="B18" ref-type="bibr">18</xref>] (<ext-link ext-link-type="uri" xlink:href="http://bionet.ncpsb.org/batman-tcm/">http://bionet.ncpsb.org/batman-tcm/</ext-link>), and the targets with similarity scores &#x0003e;10 were screened.</p></sec><sec id="sec2.4"><title>2.4. Cross-Validation of Target Proteins</title><p>To validate the target proteins and to narrow the range of possible target proteins, &#x0201c;coronary heart disease&#x0201d; was used as the keyword to search CHD-associated genes from the Comparative Toxicogenomics Database (CTD) [<xref rid="B19" ref-type="bibr">19</xref>] (<ext-link ext-link-type="uri" xlink:href="http://ctdbase.org/">http://ctdbase.org/</ext-link>, updated 2018), and the genes with inference scores &#x0003e;40 were selected. In addition, &#x0201c;coronary heart disease&#x0201d; was also used as the keyword to search CHD-associated genes from the DisGeNET database (version 6.0) [<xref rid="B20" ref-type="bibr">20</xref>]. The overlaps between the CHD-associated genes and the predicted protein targets were selected and used in the subsequent analyses.</p></sec><sec id="sec2.5"><title>2.5. Functional Enrichment Analysis</title><p>The gene ontology (GO) functional network analysis was conducted using the ClueGO&#x02009;+&#x02009;CluePedia plugins [<xref rid="B21" ref-type="bibr">21</xref>] of Cytoscape with the parameter setting as biological process, adjusted <italic>P</italic> value &#x02264;0.01, and default GO level (global option GO levels 3&#x02013;8) [<xref rid="B22" ref-type="bibr">22</xref>]. The GO functional network was visualized using Cytoscape. The Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were enriched using clusterProfiler in the R package, and the significant pathways were selected with <italic>P</italic> &#x0003c; 0.01.</p></sec><sec id="sec2.6"><title>2.6. Construction of the Protein-Protein Interaction Network</title><p>The protein-protein interactions (PPIs) were retrieved from the STRING database (version: 10.0, <ext-link ext-link-type="uri" xlink:href="http://www.string-db.org/">http://www.string-db.org/</ext-link>) with a required confidence (combined score) &#x0003e;0.9. The PPI network was visualized using Cytoscape based on the retrieved interactions.</p></sec><sec id="sec2.7"><title>2.7. Construction of the Pharmacological Network</title><p>In order to further characterize the molecular mechanisms of the effective components of the QSBD TCM granule on CHD, a pharmacological network was constructed using Cytoscape based on the herbal medicine-component-target protein-pathway data.</p></sec><sec id="sec2.8"><title>2.8. Molecular Docking</title><p>The three-dimensional (3D) structures of the key target proteins were downloaded from the RCSB Protein Data Bank (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/">http://www.rcsb.org/</ext-link>) and were modified by removing the ligand and water molecules, adding nonpolar hydrogens, amino acid optimization, and calculating Gasteiger charges using AutoDock 4.2 software. The SDF structures of the compounds were downloaded from the PubChem Compound database (<ext-link ext-link-type="uri" xlink:href="https://pubchem.ncbi.nlm.nih.gov/">https://pubchem.ncbi.nlm.nih.gov/</ext-link>), and the data were converted into a PDB format using PyMOL (version 2.0, Schr&#x000f6;dinger, LLC.) for molecular docking simulations. Molecular docking simulations were performed using AutoDock 4.2.6 with the compounds as ligands.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Identification of the Effective Components in QSBD TCM Granules</title><p>The number of chemical constituents in the four main Chinese medicinal herbs in the QSBD TCM granule was identified. Among them, 87 chemical components were identified from <italic>Astragalus mongholicus</italic>, where 20 effective components were screened with an OB&#x02009;&#x02265;&#x02009;30 and DL&#x02009;&#x02265;&#x02009;0.18. <italic>Salvia miltiorrhiza</italic> had more chemical components (202) compared to the other herbs (bighead atractylodes rhizome, 55; Rhizoma Pinelliae, 116). There were 65 effective components for <italic>Salvia miltiorrhiza</italic>, 7 effective components for bighead atractylodes rhizome, and 13 effective components for Rhizoma Pinelliae that had an OB&#x02009;&#x02265;&#x02009;30 and DL&#x02009;&#x02265;&#x02009;0.18.</p></sec><sec id="sec3.2"><title>3.2. Prediction and Screening of Drug Targets</title><p>Based on the BATMAN online tool, 222 important components with target records were predicted for the four main Chinese medicinal herbs in the QSBD TCM granule (Supplemental <xref ref-type="supplementary-material" rid="supplementary-material-1">Table 1</xref>), of which 31, 81, 75, and 35 important components with target records were predicted for Rhizoma Pinelliae, bighead atractylodes rhizome, <italic>Salvia miltiorrhiza</italic>, and <italic>Astragalus mongholicus</italic>, respectively. After screening important components using ADME and targets with scores &#x0003e;10, a total of 6 important components (magnesium lithospermate B, neocryptotanshinone II, heteratisine, daphneolone, tanshinone IIA, and tanshinone IIB) with 275 targets were obtained for <italic>Salvia miltiorrhiza</italic>, and 2 important components (soyasapogenol B and astragaloside II) with 15 targets were obtained for <italic>Astragalus mongholicus</italic> (Supplemental <xref ref-type="supplementary-material" rid="supplementary-material-1">Table 2</xref>).</p></sec><sec id="sec3.3"><title>3.3. Cross-Validation of Targets</title><p>A total of 285 CHD-associated genes with an inference score &#x0003e;40 were predicted from the CTD database, and 912 CHD-associated genes were predicted from the DisGeNET database. In all, 27 overlapped genes were obtained between the CHD-associated genes and the predicted targets (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The 27 genes were used in the subsequent analyses.</p></sec><sec id="sec3.4"><title>3.4. Functional Enrichment Analysis</title><p>The results of GO functional analysis are shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. The 27 genes were significantly enriched in 98 GO functional terms (<xref ref-type="fig" rid="fig2">Figure 2(a)</xref> and Supplemental <xref ref-type="supplementary-material" rid="supplementary-material-1">Table 3</xref>), including response to glucocorticoids, porphyrin-containing compound metabolic process, and terpenoid metabolic process. The 98 functional terms were classified into 11 categories based on the kappa coefficient and include regulation of the nitric oxide biosynthetic process, regulation of the cytokine biosynthetic process, regulation of lymphocyte-mediated immunity, and other biological processes (<xref ref-type="fig" rid="fig2">Figure 2(b)</xref>). In addition, the 27 genes were significantly enriched in 63 KEGG pathways (Supplemental <xref ref-type="supplementary-material" rid="supplementary-material-1">Table 4</xref>). The top 20 pathways are displayed in <xref ref-type="fig" rid="fig3">Figure 3</xref>, showing cytokine-cytokine receptor interactions, the TNF signaling pathway, and the IL-17 signaling pathway, among others.</p></sec><sec id="sec3.5"><title>3.5. PPI Network Analysis</title><p>Proteins and their functional interactions are at the core of cellular processes, and their connectivity network helps to understand the cellular function and biological phenomena from a system-wide level [<xref rid="B23" ref-type="bibr">23</xref>]. The STRING database allows the construction of a comprehensive and objective PPI network involving direct (physical) and indirect (functional) interactions. The PPI network consisted of 27 nodes and 172 interactions (<xref ref-type="fig" rid="fig4">Figure 4</xref>), of which albumin (ALB, degree&#x02009;=&#x02009;25), interleukin 6 (IL-6, degree&#x02009;=&#x02009;23), insulin (INS, degree&#x02009;=&#x02009;21), tumor necrosis factor (TNF, degree&#x02009;=&#x02009;20), and prostaglandin-endoperoxide synthase 2 (PTGS2, degree&#x02009;=&#x02009;19) were the main hub proteins.</p></sec><sec id="sec3.6"><title>3.6. Construction of a Pharmacological Network</title><p>The pharmacological network included 59 nodes and 189 relation pairs (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Among the 59 nodes were 2 herbal medicine nodes (<italic>Salvia miltiorrhiza</italic> and <italic>Astragalus mongholicus</italic>), 8 chemical component nodes (magnesium lithospermate B, neocryptotanshinone II, heteratisine, daphneolone, tanshinone IIA, tanshinone IIB, soyasapogenol B, and astragaloside II), 27 target protein nodes (such as TNF, IL-6, NFKB1, APOA1, APOA2, CYP1A1, and CYP1A2), and 22 pathway nodes (such as toll-like receptor signaling pathway, IL-17 signaling pathway, and TNF signaling pathway).</p></sec><sec id="sec3.7"><title>3.7. Results for Molecular Docking</title><p>Molecular docking was performed to verify the key compound-target interactions in the above analysis, including the key compounds neocryptotanshinone II and astragaloside II and key targets CYP1A1, CYP1A2, APOA1, TNF, IL-6, NFKB1, and ALB. The 3D structures of these key compounds and target proteins are shown in Supplemental <xref ref-type="supplementary-material" rid="supplementary-material-1">Figure 2</xref>. For the docking results, a total of 10 docking models were obtained, and the docking model with the best affinity (lowest binding energy) was selected as the optimal docking model. The results showed that astragaloside II had a strong affinity with ALB protein. Neocryptotanshinone II had strong affinity with multiple proteins, of which it showed the best affinity with TNF (<xref rid="tab1" ref-type="table">Table 1</xref>, <xref ref-type="fig" rid="fig6">Figure 6</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The TCM is a complex system composed of many compounds, showing complicated pharmacological activities (synergistic or antagonistic) with multiple targets and pathways. Network pharmacology meets the core concept of the holistic philosophy of TCM and has been widely used to investigate the detailed compound-target and target-pathway relationships of herbs used for the treatment of complicated diseases [<xref rid="B24" ref-type="bibr">24</xref>&#x02013;<xref rid="B26" ref-type="bibr">26</xref>]. In the current study, two key herbal medicines (<italic>Salvia miltiorrhiza</italic> and <italic>Astragalus mongholicus</italic>), corresponding to 8 key chemical components, were identified, and these chemical components were found to target 27 genes and major gene-regulated pathways.</p><p>The recruitment of inflammatory cells to injured vascular tissues could contribute to the formation of plaques by secreting inflammatory mediators. Therefore, inflammatory markers have been considered as risk factors for CHD [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B27" ref-type="bibr">27</xref>]. IL-6 is an inflammatory cytokine secreted by activated macrophages and lymphocytes; the risk factors of CHD might elevate IL-6 levels. Social disruption stress showed effects on the increase of atherosclerotic plaque areas in apolipoprotein E<sup>&#x02212;/&#x02212;</sup> mice, probably by upregulating IL-6 levels [<xref rid="B28" ref-type="bibr">28</xref>]. Danesh et al. showed that there were significant correlations between elevated IL-6 levels and increased CHD risk, suggesting an underlying relevance of pathways involving IL-6 in the pathogenesis of CHD [<xref rid="B29" ref-type="bibr">29</xref>]. Hou et al. indicated that circulating IL-6 was associated with different kinds of cardiovascular diseases and that IL-6 showed an effect on platelets which were essential for blood coagulation [<xref rid="B30" ref-type="bibr">30</xref>]. Hot et al. demonstrated that IL-17 coupled with TNF<italic>&#x003b1;</italic> had a synergistic induction on the generation of IL-6 and had significant procoagulant and prothrombotic effects in blood vessels [<xref rid="B31" ref-type="bibr">31</xref>]. In this study, several genes (TNF, IL-6, NFKB1, etc.) regulated by neocryptotanshinone II were implicated in inflammation-related pathways, such as the IL-17 signaling pathway, TNF signaling pathway, and Th17 cell differentiation pathway. Therefore, we speculated that neocryptotanshinone II exerted pharmacological activities on CHD by regulating inflammatory cytokines and their signaling pathways.</p><p>Albumin (ALB) is a 69&#x02009;kDa protein that normally accounts for more than 50% of the total plasma protein content, functioning in regulating blood plasma colloid osmotic pressure, and acts as a carrier protein [<xref rid="B32" ref-type="bibr">32</xref>]. Low levels of serum ALB have been found to be associated with different kinds of cardiovascular diseases, including venous thromboembolism, CHD, and incident ischemic heart disease [<xref rid="B33" ref-type="bibr">33</xref>]. Chien et al. indicated that low levels of serum ALB were related to an increase in hard cardiovascular events and all-cause mortality for patients with stable CHD, suggesting the worse prognosis of low levels of serum ALB in stable CHD [<xref rid="B34" ref-type="bibr">34</xref>]. It was reported that decreased serum ALB levels may indicate worse prognosis of patients with CHD, probably by increasing autophagy [<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>]. In our study, ALB was a hub gene with the highest degree in the PPI network and was a target gene of astragaloside II in the pharmacological network. Astragaloside II is an active compound from the medicinal herb Radix Astragali and has been reported to enhance T-cell activation [<xref rid="B37" ref-type="bibr">37</xref>], inhibit autophagy of hepatocellular carcinoma cells [<xref rid="B38" ref-type="bibr">38</xref>], and enhance the secretion of adiponectin in primary adipocytes [<xref rid="B39" ref-type="bibr">39</xref>]. Here, we suggested that astragaloside II played roles in the treatment of CHD by targeting ALB and regulating the level of ALB in blood.</p><p>An elevated low-density lipoprotein cholesterol level is one of the major causes of CHD and is an indispensable and independent index to predict the risk of CHD [<xref rid="B40" ref-type="bibr">40</xref>]. Cytochrome P450 family 1 subfamily A member 1 (CYP1A1) and CYP1A2 encode members of the cytochrome P450 superfamily of enzymes, which catalyze multiple reactions associated with drug metabolism, as well as the synthesis of cholesterol and steroids [<xref rid="B41" ref-type="bibr">41</xref>&#x02013;<xref rid="B43" ref-type="bibr">43</xref>]. Apolipoprotein A-I (APOA1) and apolipoprotein A-II (APOA2) are major protein components of high-density lipoprotein (HDL) particles in plasma, functioning in the transportation of cholesterol on HDL [<xref rid="B44" ref-type="bibr">44</xref>]. Human and recombinant APOA1 have been reported to promote HDL-mediated cholesterol efflux and improve atherosclerosis [<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>]. In this study, CYP1A1, CYP1A2, APOA1, and APOA2 were all targets of neocryptotanshinone II in the pharmacological network. Neocryptotanshinone II is the active compound from the medicinal herb <italic>Salvia miltiorrhiza</italic>. Liu et al. suggested that Radix <italic>Salvia miltiorrhiza</italic> compounds could decrease the risk of CHD by improving the biochemical indices (reducing the levels of triglycerides, cholesterol, and lipids, while increasing the levels of apolipoprotein A/B/E and total bilirubin) of patients with CHD [<xref rid="B9" ref-type="bibr">9</xref>]. Therefore, we concluded that neocryptotanshinone II played roles in the treatment of CHD by targeting CYP1A1, CYP1A2, APOA1, and APOA2 to regulate cholesterol levels.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>Network pharmacological analysis revealed that 8 key compounds in <italic>Salvia miltiorrhiza</italic> and <italic>Astragalus mongholicus</italic> targeted 27 genes and the biochemical pathways in CHD they are involved in. The genes TNF, IL-6, NFKB1, ALB, CYP1A1, CYP1A2, APOA1, and APOA2 might be important targets of the key active compounds neocryptotanshinone II and astragaloside II. The genes targeted by these key active compounds might regulate inflammation-related pathways and the level of albumin and cholesterol in CHD.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by the National Program on Key Basic Research Project (973 Program) (Grant no. 2013CB531704), the National Natural Science Foundation of China (Grant No. 81703970), Open Foundation Project of Key Laboratory of Theory and Application of Viscera in Chinese Medicine (Grant No. zyzx1607), General Project Science and Technology of Education Department of Liaoning Province(Grant No. L201715), Open Foundation Project of Key Laboratory of Theory and Application of Viscera in Chinese Medicine (Grant No. zyzx1808).</p></ack><sec sec-type="data-availability"><title>Data Availability</title><p>All the data generated or analyzed during this study are included in this published article.</p></sec><sec sec-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest regarding the publication of this paper.</p></sec><sec><title>Authors' Contributions</title><p>Fan Zhang and Yue Liu contributed equally to this work.</p></sec><sec sec-type="supplementary-material" id="supplementary-material-1"><title>Supplementary Materials</title><supplementary-material content-type="local-data" id="supp-1"><label>Supplementary Materials</label><caption><p>Supplemental Table 1: the 222 components with target records for the four main Chinese medicinal herbs. Supplemental Table 2: the component-target pairs for the important components as screened by ADME. Supplemental Table 3: enriched GO functional terms for the 27 target genes. Supplemental Table 4: enriched KEGG pathways for the 27 target genes.</p></caption><media xlink:href="1062325.f1.zip"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Townsend</surname><given-names>N.</given-names></name><name><surname>Wilson</surname><given-names>L.</given-names></name><name><surname>Bhatnagar</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Cardiovascular disease in Europe: epidemiological update 2016</article-title><source><italic toggle="yes">European Heart Journal</italic></source><year>2016</year><volume>37</volume><issue>42</issue><fpage>3232</fpage><lpage>3245</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehw334</pub-id><pub-id pub-id-type="other">2-s2.0-85015746996</pub-id><pub-id pub-id-type="pmid">27523477</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Inflammatory biomarkers of coronary heart disease</article-title><source><italic toggle="yes">Frontiers in Bioscience (Scholar Edition)</italic></source><year>2018</year><volume>10</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.2741/s508</pub-id><pub-id pub-id-type="pmid">28930526</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhabue</surname><given-names>E.</given-names></name><name><surname>Thiboutot</surname><given-names>J.</given-names></name><name><surname>Cheng</surname><given-names>J. W.</given-names></name><etal/></person-group><article-title>New and emerging risk factors for coronary heart disease</article-title><source><italic toggle="yes">American Journal of the Medical Sciences</italic></source><year>2014</year><volume>347</volume><issue>2</issue><fpage>151</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1097/MAJ.0b013e31828aab45</pub-id><pub-id pub-id-type="other">2-s2.0-84894203224</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirtz</surname><given-names>P. H.</given-names></name><name><surname>von K&#x000e4;nel</surname><given-names>R.</given-names></name></person-group><article-title>Psychological stress, inflammation, and coronary heart disease</article-title><source><italic toggle="yes">Current Cardiology Reports</italic></source><year>2017</year><volume>19</volume><issue>11</issue><fpage>p. 111</fpage><pub-id pub-id-type="doi">10.1007/s11886-017-0919-x</pub-id><pub-id pub-id-type="other">2-s2.0-85029767278</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>P.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Traditional Chinese medicine on the treatment of coronary heart disease in recent 20 years</article-title><source><italic toggle="yes">Journal of Alternative and Complementary Medicine</italic></source><year>2017</year><volume>23</volume><issue>9</issue><fpage>659</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1089/acm.2016.0420</pub-id><pub-id pub-id-type="other">2-s2.0-85031910590</pub-id><pub-id pub-id-type="pmid">28497986</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Niimi</surname><given-names>M.</given-names></name><name><surname>Watanabe</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Treatment of atherosclerosis by traditional Chinese medicine: questions and quandaries</article-title><source><italic toggle="yes">Atherosclerosis</italic></source><year>2018</year><volume>277</volume><fpage>136</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2018.08.039</pub-id><pub-id pub-id-type="other">2-s2.0-85053059957</pub-id><pub-id pub-id-type="pmid">30212682</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Meng</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The therapeutical effect of Chinese medicine for the treatment of atherosclerotic coronary heart disease</article-title><source><italic toggle="yes">Current Pharmaceutical Design</italic></source><year>2017</year><volume>23</volume><issue>34</issue><fpage>5086</fpage><lpage>5096</lpage><pub-id pub-id-type="doi">10.2174/1381612823666170803101602</pub-id><pub-id pub-id-type="other">2-s2.0-85042742286</pub-id><pub-id pub-id-type="pmid">28782475</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A traditional Chinese medicine therapy for coronary heart disease after percutaneous coronary intervention: a meta-analysis of randomized, double-blind, placebo-controlled trials</article-title><source><italic toggle="yes">Bioscience Reports</italic></source><year>2018</year><volume>38</volume><issue>5</issue><pub-id pub-id-type="doi">10.1042/BSR20180973</pub-id><pub-id pub-id-type="other">2-s2.0-85055138156</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name><name><surname>Cong</surname><given-names>L.</given-names></name><name><surname>Jia</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name></person-group><article-title>Danshen (Salvia miltiorrhiza) compounds improve the biochemical indices of the patients with coronary heart disease</article-title><source><italic toggle="yes">Evidence-Based Complementary and Alternative Medicine</italic></source><year>2016</year><volume>2016</volume><fpage>9</fpage><pub-id pub-id-type="publisher-id">9781715</pub-id><pub-id pub-id-type="doi">10.1155/2016/9781715</pub-id><pub-id pub-id-type="other">2-s2.0-84976386605</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Effect of treating stable angina pectoris from spleen on quality of life in patients</article-title><source><italic toggle="yes">Liaoning Journal of Traditional Chinese Medicine</italic></source><year>2018</year><volume>45</volume><issue>7</issue><fpage>1345</fpage><lpage>1350</lpage></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Effect of &#x0201c;treatment according with the spleen&#x0201d; on Hcy in patients with stable angina pectoris and spleen deficiency phlegm syndrome and correlation analysis of Hcy</article-title><source><italic toggle="yes">Lishizhen Medicine and Materia Medica Research</italic></source><year>2018</year><volume>29</volume><issue>5</issue><fpage>1122</fpage><lpage>1125</lpage></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Development of theory of phlegm and blood stasis of Yang Guanlin</article-title><source><italic toggle="yes">Liaoning Journal of Traditional Chinese Medicine</italic></source><year>2017</year><volume>44</volume><issue>11</issue><fpage>2280</fpage><lpage>2283</lpage></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Integrating network pharmacology and pharmacological evaluation for deciphering the action mechanism of herbal formula zuojin pill in suppressing hepatocellular carcinoma</article-title><source><italic toggle="yes">Frontiers in Pharmacology</italic></source><year>2019</year><volume>10</volume><fpage>p. 1185</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01185</pub-id><pub-id pub-id-type="other">2-s2.0-85074212361</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>W.</given-names></name></person-group><article-title>Network pharmacology of yougui pill combined with Buzhong Yiqi decoction for the treatment of sexual dysfunction</article-title><source><italic toggle="yes">Evidence-Based Complementary and Alternative Medicine</italic></source><year>2019</year><volume>2019</volume><fpage>10</fpage><pub-id pub-id-type="publisher-id">1243743</pub-id><pub-id pub-id-type="doi">10.1155/2019/1243743</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>M.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>A network pharmacology integrated pharmacokinetics strategy for uncovering pharmacological mechanism of compounds absorbed into the blood of Dan-Lou tablet on coronary heart disease</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2019</year><volume>242</volume><pub-id pub-id-type="publisher-id">112055</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2019.112055</pub-id><pub-id pub-id-type="other">2-s2.0-85068253137</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ru</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>TCMSP: a database of systems pharmacology for drug discovery from herbal medicines</article-title><source><italic toggle="yes">Journal of Cheminformatics</italic></source><year>2014</year><volume>6</volume><fpage>p. 13</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-6-13</pub-id><pub-id pub-id-type="other">2-s2.0-84899981355</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>F.</given-names></name><name><surname>Hashida</surname><given-names>M.</given-names></name></person-group><article-title>In silico approaches for predicting ADME properties of drugs</article-title><source><italic toggle="yes">Drug Metabolism and Pharmacokinetics</italic></source><year>2004</year><volume>19</volume><issue>5</issue><fpage>327</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.2133/dmpk.19.327</pub-id><pub-id pub-id-type="other">2-s2.0-16644369555</pub-id><pub-id pub-id-type="pmid">15548844</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>BATMAN-TCM: a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2016</year><volume>6</volume><fpage>p. 21146</fpage><pub-id pub-id-type="doi">10.1038/srep21146</pub-id><pub-id pub-id-type="other">2-s2.0-84958242317</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>A. P.</given-names></name><name><surname>Grondin</surname><given-names>C. J.</given-names></name><name><surname>Johnson</surname><given-names>R. J.</given-names></name><etal/></person-group><article-title>The comparative toxicogenomics database: update 2019</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2019</year><volume>47</volume><issue>D1</issue><fpage>D948</fpage><lpage>D954</lpage><pub-id pub-id-type="doi">10.1093/nar/gky868</pub-id><pub-id pub-id-type="other">2-s2.0-85059795504</pub-id><pub-id pub-id-type="pmid">30247620</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pi&#x000f1;ero</surname><given-names>J.</given-names></name><name><surname>Ram&#x000ed;rez-Anguita</surname><given-names>J. M.</given-names></name><name><surname>Sa&#x000fc;ch-Pitarch</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The DisGeNET knowledge platform for disease genomics: 2019 update</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2020</year><volume>48</volume><issue>D1</issue><fpage>D845</fpage><lpage>D855</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1021</pub-id><pub-id pub-id-type="pmid">31680165</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bindea</surname><given-names>G.</given-names></name><name><surname>Mlecnik</surname><given-names>B.</given-names></name><name><surname>Hackl</surname><given-names>H.</given-names></name><etal/></person-group><article-title>ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks</article-title><source><italic toggle="yes">Bioinformatics</italic></source><year>2019</year><volume>25</volume><issue>8</issue><fpage>1091</fpage><lpage>1093</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp101</pub-id><pub-id pub-id-type="other">2-s2.0-64549104807</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>D. W.</given-names></name><name><surname>Sherman</surname><given-names>B. T.</given-names></name><name><surname>Tan</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists</article-title><source><italic toggle="yes">Genome Biology</italic></source><year>2017</year><volume>8</volume><issue>9</issue><fpage>p. R183</fpage><pub-id pub-id-type="doi">10.1186/gb-2007-8-9-r183</pub-id><pub-id pub-id-type="other">2-s2.0-41349115432</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szklarczyk</surname><given-names>D.</given-names></name><name><surname>Gable</surname><given-names>A. L.</given-names></name><name><surname>Lyon</surname><given-names>D.</given-names></name><etal/></person-group><article-title>STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets</article-title><source><italic toggle="yes">Nucleic Acids Research</italic></source><year>2018</year><volume>47</volume><issue>D1</issue><fpage>D607</fpage><lpage>D613</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1131</pub-id><pub-id pub-id-type="other">2-s2.0-85059797047</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W. Y.</given-names></name><name><surname>Lee</surname><given-names>C. Y.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Kim</surname><given-names>C. E.</given-names></name></person-group><article-title>The methodological trends of traditional herbal medicine employing network pharmacology</article-title><source><italic toggle="yes">Biomolecules</italic></source><year>2019</year><volume>9</volume><issue>8</issue><fpage>p. 362</fpage><pub-id pub-id-type="doi">10.3390/biom9080362</pub-id><pub-id pub-id-type="other">2-s2.0-85071280070</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Network pharmacology study of traditional Chinese medicines for stroke treatment and effective constituents screening</article-title><source><italic toggle="yes">Journal of Ethnopharmacology</italic></source><year>2019</year><volume>242</volume><pub-id pub-id-type="publisher-id">112044</pub-id><pub-id pub-id-type="doi">10.1016/j.jep.2019.112044</pub-id><pub-id pub-id-type="other">2-s2.0-85068470378</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Network pharmacology study on the active components of Pterocypsela elata and the mechanism of their effect against cerebral ischemia</article-title><source><italic toggle="yes">Drug Design, Development and Therapy</italic></source><year>2019</year><volume>13</volume><fpage>3009</fpage><lpage>3019</lpage><pub-id pub-id-type="doi">10.2147/DDDT.S207955</pub-id><pub-id pub-id-type="other">2-s2.0-85072745997</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Sun</surname><given-names>K.</given-names></name><name><surname>Zhao</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Inflammatory biomarkers of coronary heart disease</article-title><source><italic toggle="yes">Frontiers in Bioscience (Landmark Edition)</italic></source><year>2018</year><volume>10</volume><fpage>185</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.2741/s508</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bernberg</surname><given-names>E.</given-names></name><name><surname>Ulleryd</surname><given-names>M. A.</given-names></name><name><surname>Johansson</surname><given-names>M. E.</given-names></name><name><surname>Bergstr&#x000f6;m</surname><given-names>G. M.</given-names></name></person-group><article-title>Social disruption stress increases IL-6 levels and accelerates atherosclerosis in ApoE<sup>&#x02212;/&#x02212;</sup> mice</article-title><source><italic toggle="yes">Atherosclerosis</italic></source><year>2011</year><volume>221</volume><issue>2</issue><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2011.11.041</pub-id><pub-id pub-id-type="other">2-s2.0-84858705543</pub-id><pub-id pub-id-type="pmid">22284955</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danesh</surname><given-names>J.</given-names></name><name><surname>Kaptoge</surname><given-names>S.</given-names></name><name><surname>Mann</surname><given-names>A. G.</given-names></name><etal/></person-group><article-title>Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review</article-title><source><italic toggle="yes">PLoS Medicine</italic></source><year>2008</year><volume>5</volume><issue>4</issue><fpage>p. e78</fpage><pub-id pub-id-type="doi">10.1371/journal.pmed.0050078</pub-id><pub-id pub-id-type="other">2-s2.0-43249118045</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>T.</given-names></name><name><surname>Tieu</surname><given-names>B. C.</given-names></name><name><surname>Ray</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Roles of IL-6-gp130 signaling in vascular inflammation</article-title><source><italic toggle="yes">Current Cardiology Reviews</italic></source><year>2008</year><volume>4</volume><issue>3</issue><fpage>179</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.2174/157340308785160570</pub-id><pub-id pub-id-type="other">2-s2.0-54649084455</pub-id><pub-id pub-id-type="pmid">19936194</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hot</surname><given-names>A.</given-names></name><name><surname>Lenief</surname><given-names>V.</given-names></name><name><surname>Miossec</surname><given-names>P.</given-names></name></person-group><article-title>Combination of IL-17 and TNF<italic>&#x003b1;</italic> induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells</article-title><source><italic toggle="yes">Annals of the Rheumatic Diseases</italic></source><year>2012</year><volume>71</volume><issue>5</issue><fpage>768</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1136/annrheumdis-2011-200468</pub-id><pub-id pub-id-type="other">2-s2.0-84859491118</pub-id><pub-id pub-id-type="pmid">22258491</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Martinez</surname><given-names>R.</given-names></name><name><surname>Caraceni</surname><given-names>P.</given-names></name><name><surname>Bernardi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications</article-title><source><italic toggle="yes">Hepatology</italic></source><year>2013</year><volume>58</volume><issue>5</issue><fpage>1836</fpage><lpage>1846</lpage><pub-id pub-id-type="doi">10.1002/hep.26338</pub-id><pub-id pub-id-type="other">2-s2.0-84887017005</pub-id><pub-id pub-id-type="pmid">23423799</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arques</surname><given-names>S.</given-names></name></person-group><article-title>Human serum albumin in cardiovascular diseases</article-title><source><italic toggle="yes">European Journal of Internal Medicine</italic></source><year>2018</year><volume>52</volume><fpage>8</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2018.04.014</pub-id><pub-id pub-id-type="other">2-s2.0-85045838373</pub-id><pub-id pub-id-type="pmid">29680174</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>S. C.</given-names></name><name><surname>Chen</surname><given-names>C. Y.</given-names></name><name><surname>Leu</surname><given-names>H. B.</given-names></name><etal/></person-group><article-title>Association of low serum albumin concentration and adverse cardiovascular events in stable coronary heart disease</article-title><source><italic toggle="yes">International Journal of Cardiology</italic></source><year>2017</year><volume>241</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2017.04.003</pub-id><pub-id pub-id-type="other">2-s2.0-85017453199</pub-id><pub-id pub-id-type="pmid">28413113</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Fan</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Sun</surname><given-names>X.</given-names></name></person-group><article-title>Possible intermediary role of autophagy in serum albumin decrease-associated cardiovascular events among patients with coronary heart disease</article-title><source><italic toggle="yes">International Journal of Cardiology</italic></source><year>2018</year><volume>250</volume><fpage>p. 64</fpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2017.09.006</pub-id><pub-id pub-id-type="other">2-s2.0-85030852835</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>S. C.</given-names></name><name><surname>Yeh</surname><given-names>H. I.</given-names></name></person-group><article-title>Reply to letter to the editor: &#x0201c;possible intermediary role of autophagy in serum albumin decrease-associated cardiovascular events among patients with coronary heart disease</article-title><source><italic toggle="yes">International Journal of Cardiology</italic></source><year>2018</year><volume>250</volume><fpage>p. 65</fpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2017.09.212</pub-id><pub-id pub-id-type="other">2-s2.0-85030784246</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wan</surname><given-names>C. P.</given-names></name><name><surname>Gao</surname><given-names>L. X.</given-names></name><name><surname>Hou</surname><given-names>L. F.</given-names></name><etal/></person-group><article-title>Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity</article-title><source><italic toggle="yes">Acta Pharmacologica Sinica</italic></source><year>2013</year><volume>34</volume><issue>4</issue><fpage>522</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1038/aps.2012.208</pub-id><pub-id pub-id-type="other">2-s2.0-84877295488</pub-id><pub-id pub-id-type="pmid">23524573</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Su</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Astragaloside II sensitizes human hepatocellular carcinoma cells to 5-fluorouracil via suppression of autophagy</article-title><source><italic toggle="yes">Journal of Pharmacy and Pharmacology</italic></source><year>2017</year><volume>69</volume><issue>6</issue><fpage>743</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1111/jphp.12706</pub-id><pub-id pub-id-type="other">2-s2.0-85014590753</pub-id><pub-id pub-id-type="pmid">28266023</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Hoo</surname><given-names>R. L.</given-names></name><etal/></person-group><article-title>Selective elevation of adiponectin production by the natural compounds derived from a medicinal herb alleviates insulin resistance and glucose intolerance in obese mice</article-title><source><italic toggle="yes">Endocrinology</italic></source><year>2009</year><volume>150</volume><issue>2</issue><fpage>625</fpage><lpage>633</lpage><pub-id pub-id-type="doi">10.1210/en.2008-0999</pub-id><pub-id pub-id-type="other">2-s2.0-59649117072</pub-id><pub-id pub-id-type="pmid">18927219</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H. H.</given-names></name><name><surname>Garruti</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Portincasa</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>D. Q.</given-names></name></person-group><article-title>Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport</article-title><source><italic toggle="yes">Annals of Hepatology</italic></source><year>2017</year><volume>16</volume><issue>1</issue><fpage>S527</fpage><lpage>S542</lpage><pub-id pub-id-type="doi">10.5604/01.3001.0010.5495</pub-id><pub-id pub-id-type="other">2-s2.0-85046080199</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guengerich</surname><given-names>F. P.</given-names></name><name><surname>Waterman</surname><given-names>M. R.</given-names></name><name><surname>Egli</surname><given-names>M.</given-names></name></person-group><article-title>Recent structural insights into cytochrome P450 function</article-title><source><italic toggle="yes">Trends in Pharmacological Sciences</italic></source><year>2016</year><volume>37</volume><issue>8</issue><fpage>625</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2016.05.006</pub-id><pub-id pub-id-type="other">2-s2.0-84971647399</pub-id><pub-id pub-id-type="pmid">27267697</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tornio</surname><given-names>A.</given-names></name><name><surname>Backman</surname><given-names>J. T.</given-names></name></person-group><article-title>Cytochrome P450 in pharmacogenetics: an update</article-title><source><italic toggle="yes">Advances in Pharmacology</italic></source><year>2018</year><volume>83</volume><fpage>3</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/bs.apha.2018.04.007</pub-id><pub-id pub-id-type="other">2-s2.0-85047217845</pub-id><pub-id pub-id-type="pmid">29801580</pub-id></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>A&#x0010d;imovi&#x0010d;</surname><given-names>J.</given-names></name><name><surname>Goyal</surname><given-names>S.</given-names></name><name><surname>Ko&#x00161;ir</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Cytochrome P450 metabolism of the post-lanosterol intermediates explains enigmas of cholesterol synthesis</article-title><source><italic toggle="yes">Scientific Reports</italic></source><year>2016</year><volume>6</volume><fpage>p. 28462</fpage><pub-id pub-id-type="doi">10.1038/srep28462</pub-id><pub-id pub-id-type="other">2-s2.0-84975744681</pub-id><pub-id pub-id-type="pmid">27334049</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tailleux</surname><given-names>A.</given-names></name><name><surname>Duriez</surname><given-names>P.</given-names></name><name><surname>Fruchart</surname><given-names>J. C.</given-names></name><name><surname>Clavey</surname><given-names>V.</given-names></name></person-group><article-title>Apolipoprotein A-II, HDL metabolism and atherosclerosis</article-title><source><italic toggle="yes">Atherosclerosis</italic></source><year>2016</year><volume>164</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/S0021-9150(01)00751-1</pub-id><pub-id pub-id-type="other">2-s2.0-0035996574</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michael Gibson</surname><given-names>C.</given-names></name><name><surname>Korjian</surname><given-names>S.</given-names></name><name><surname>Tricoci</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in ischemic syndromes I)</article-title><source><italic toggle="yes">Circulation</italic></source><year>2016</year><volume>134</volume><issue>24</issue><fpage>1918</fpage><lpage>1930</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.116.025687</pub-id><pub-id pub-id-type="other">2-s2.0-84996938010</pub-id><pub-id pub-id-type="pmid">27881559</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gille</surname><given-names>A.</given-names></name><name><surname>D&#x02019;Andrea</surname><given-names>D.</given-names></name><name><surname>Tortorici</surname><given-names>M. A.</given-names></name><name><surname>Hartel</surname><given-names>G.</given-names></name><name><surname>Wright</surname><given-names>S. D.</given-names></name></person-group><article-title>CSL112 (apolipoprotein A-I [human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients</article-title><source><italic toggle="yes">Arteriosclerosis, Thrombosis, and Vascular Biology</italic></source><year>2018</year><volume>38</volume><issue>4</issue><fpage>953</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1161/atvbaha.118.310538</pub-id><pub-id pub-id-type="other">2-s2.0-85044397571</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Venn diagrams for cross-validation targets.</p></caption><graphic xlink:href="ECAM2020-1062325.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>The results of gene ontology (GO) functional analyses. (a) GO functional network for the 27 target genes. The nodes represent GO functional terms; larger nodes represent more significant <italic>P</italic> values; lines represent the correlation between functional terms. (b) Pie chart showing the clusters of the GO functional terms.</p></caption><graphic xlink:href="ECAM2020-1062325.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Bubble chart of top 20 pathways. Larger dots represent a larger proportion of the number of enriched genes to the total number of genes; the color gradient from blue to pink represents decreasing <italic>P</italic> values.</p></caption><graphic xlink:href="ECAM2020-1062325.003"/></fig><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The protein-protein interaction (PPI) network. The nodes represent target proteins; the node size represents the degree of each node; lines represent the interactions between two nodes.</p></caption><graphic xlink:href="ECAM2020-1062325.004"/></fig><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>The pharmacological network. The diamonds represent herbal medicines; squares represent chemical components; circular nodes represent target genes; hexagons represent pathways. HUANGQI, <italic>Astragalus mongholicus</italic>; DANSHEN, <italic>Salvia miltiorrhiza</italic>.</p></caption><graphic xlink:href="ECAM2020-1062325.005"/></fig><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Molecular models of astragaloside II and neocryptotanshinone II binding to their predicted protein targets. ALB protein showed interaction with the astragaloside II molecule. The proteins CYP1A1, CYP1A2, APOA1, TNF, IL-6, and NFKB1 showed interactions with the neocryptotanshinone II molecule. Off-white diagrams represent receptors (target proteins), and pink diagrams represent ligands (compounds).</p></caption><graphic xlink:href="ECAM2020-1062325.006"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>The binding energies of the optimal docking models.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Compounds</th><th align="center" rowspan="1" colspan="1">Target proteins</th><th align="center" rowspan="1" colspan="1">Binding energy</th><th align="center" rowspan="1" colspan="1">Cluster RMSD</th><th align="center" rowspan="1" colspan="1">Reference RMSD</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Astragaloside II</td><td align="center" rowspan="1" colspan="1">ALB</td><td align="center" rowspan="1" colspan="1">&#x02212;12.27</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">12.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Neocryptotanshinone II</td><td align="center" rowspan="1" colspan="1">APOA1</td><td align="center" rowspan="1" colspan="1">&#x02212;6.80</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">111.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Neocryptotanshinone II</td><td align="center" rowspan="1" colspan="1">CYP1A1</td><td align="center" rowspan="1" colspan="1">&#x02212;9.50</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">45.40</td></tr><tr><td align="left" rowspan="1" colspan="1">Neocryptotanshinone II</td><td align="center" rowspan="1" colspan="1">CYP1A2</td><td align="center" rowspan="1" colspan="1">&#x02212;9.28</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">35.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Neocryptotanshinone II</td><td align="center" rowspan="1" colspan="1">IL-6</td><td align="center" rowspan="1" colspan="1">&#x02212;7.45</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">92.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Neocryptotanshinone II</td><td align="center" rowspan="1" colspan="1">NFKB1</td><td align="center" rowspan="1" colspan="1">&#x02212;7.15</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">14.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Neocryptotanshinone II</td><td align="center" rowspan="1" colspan="1">TNF</td><td align="center" rowspan="1" colspan="1">&#x02212;9.53</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">23.12</td></tr></tbody></table></table-wrap></floats-group></article>